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Antitumor Activity of cGAMP via 
Stimulation of cGAS-cGAMP-
STING-IRF3 Mediated Innate 
Immune Response
Tiejun Li2,*, Hao Cheng1,*, Hong Yuan1,*, Qiming Xu1, Chang Shu3, Yuefan Zhang2, 
Pengbiao Xu1, Jason Tan3, Yaocheng Rui2, Pingwei Li3 & Xiangshi Tan1
Immunotherapy is one of the key strategies for cancer treatment. The cGAS-cGAMP-STING-IRF3 
pathway of cytosolic DNA sensing plays a pivotal role in antiviral defense. We report that the STING 
activator cGAMP possesses significant antitumor activity in mice by triggering the STING-dependent 
pathway directly. cGAMP enhances innate immune responses by inducing production of cytokines 
such as interferon-β, interferon-γ, and stimulating dendritic cells activation, which induces the cross-
priming of CD8+ T cells. The antitumor mechanism of cGAMP was verified by STING and IRF3, which 
were up-regulated upon cGAMP treatment. STING-deficiency dramatically reduced the antitumor 
effect of cGAMP. Furthermore, cGAMP improved the antitumor activity of 5-FU, and clearly reduced the 
toxicity of 5-FU. These results demonstrated that cGAMP is a novel antitumor agent and has potential 
applications in cancer immunotherapy.
Cancer is one of the most frequent causes of death worldwide despite significant improvements in cancer thera-
pies during the past decades. Immunotherapy provides renovating treatment of cancer patients, and is becoming 
one of the key strategies to cure cancer1. Although cancer immunotherapy exhibits promising perspective, and 
is milder and more manageable than traditional or targeted cancer therapy, the molecular mechanism for tumor 
immunogenicity is usually unclear. Therefore, cancer immunotherapy strategies are still limited. It has been 
suggested that the optimal cancer immunotherapeutics will come from a combination of therapeutic strategies 
involving the manipulation of innate immunity, which plays a critical role in promoting T cell mediated immune 
response to cancer2. Immunotherapy is the most effective when an immune response is already underway, with 
activated T cells and dying tumor cells3. The generation of immunity to cancer is a cyclic process that can be 
self-propagating, leading to an accumulation of immune-stimulatory factors that in principle should amplify and 
broaden T cell response1,2,4. Induction of potent tumor-specific cytotoxic T-cell responses is one set of funda-
mental objectives in anticancer therapeutic strategies5. This event requires that antigen-presenting cells (APCs) 
present tumor-associated antigens (Ag) on their MHC class-I molecule (cross-presentation) to stimulate native 
CD8+ T cells (a process termed cross-priming). Dendritic cells (DCs) are the most important APCs which pres-
ent tumor derived antigens in vivo6,7. DCs are particularly keen on this task and can induce the cross-priming of 
CD8+ T cells, when they are exposed to danger or inflammatory signals that stimulate their activation8. Recently, 
in vitro and in vivo studies have suggested that Type-I interferon (IFN), including IFN-α and IFN-β , stimulates 
cross-priming by DC against tumor-associated antigens is a key mechanism for cancer immune surveillance and 
can be targeted to boost anti-tumor CD8+ T-cell responses8.
Recent investigations have identified cyclic GMP-AMP synthase (cGAS) as a key cytosolic DNA sen-
sor in innate immunity9. cGAS is activated by double strand DNA (dsDNA) and catalyzes the synthesis of a 
non-canonical cyclic dinucleotide 2′ , 3′ cGAMP (cGAMP)10–13. cGAMP serves as a second messenger to induce 
the production of IFN-β and other cytokines via the adaptor protein stimulator of interferon genes complex 
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(STING) locating in the ER membrane14. cGAMP induces a conformational change of STING, leading to the 
recruitment and activation of protein kinase TBK1 at the signaling complex. The transcription factor inter-
feron regulatory factor 3 (IRF3) is then recruited to the signaling complex and phosphorylated by TBK111,15. 
Phosphorylated IRF3 initiates the expression of IFN-β , which regulates the expression of over two hundred 
interferon-inducible genes that can down regulate protein synthesis, induce cell growth arrest and apoptosis, thus 
creating an antiviral effect15–17. Recent studies showed that STING-dependent cytosolic DNA sensing can mediate 
innate immune recognition of immunogenic tumors, and promote type-I IFN dependent antitumor immunity 
after radiation therapy18,19. IFN-γ can also exert antitumor effect in vivo via the tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) pathway, which causes apoptosis of tumor cells20. The host STING pathway 
can play a critical role in the therapeutic efficacy of cancer immunotherapies. To understand the structural basis 
for cGAMP to activate STING, the crystal structures of cGAS bound to dsDNA and STING bound to cGAMP 
have recently been determined respectively21–26. A novel cGAS-cGAMP-STING-IRF3 pathway of cytosolic 
sensing and signaling has been verified to mediate innate immune response, and plays pivotal roles in antiviral 
defense27. Viruses can transfer the antiviral second messenger cGAMP between cells28. The transfer of cGAMP by 
viruses may represent a defense mechanism to propagate immune responses to uninfected target cells29. cGAMP 
is a critical stimulator of cGAS-cGAMP-STING-IRF3-mediated innate immune responses and is a high affinity 
endogenous activator of STING, we reasoned that cGAMP should also promote antitumor immune responses 
in addition to its antiviral activity. We synthesized cGAMP using recombinant cGAS enzyme, and purified it by 
ion exchange chromatography to over 95% purity. And then, we herein systematically investigated the antitumor 
activity of cGAMP against murine Colon 26 adenocarcinoma in mouse models. Our results showed that cGAMP 
has potent antitumor activity in vivo. cGAMP induces the expression of a variety of cytokines and stimulate the 
activation of DCs. In addition, cGAMP also improves the antitumor activity of 5-FU and reduces the toxic side 
effects when used in combination with 5-FU. Our results established a solid basis for the development of cGAMP 
as a potential new antitumor immunotherapy drug.
Results
cGAMP Possesses Potent Antitumor Activity against Murine Colon 26 Adenocarcinoma. It has 
been demonstrated that cGAMP is an endogenous activator of STING and it is generated in mammalian cells 
by cGAS in response to double-strand DNA in the cytoplasm13,19,30. We hypothesized that exogenous cGAMP 
treatment might potentiate the antitumor effect by enhancing STING activation. To test this hypothesis, colon 26 
cell suspensions were injected subcutaneously into the right flank of mice to develop tumor-bearing mice, which 
were treated with cGAMP daily at dosages of 5, 10 and 20 mg/kg in different group mice for 20 days. Tumor 
volumes and weights of mice were measured daily. On the 20th day, all mice were weighed and sacrificed, and 
then tumors were isolated and measured. As shown in Fig. 1A,B, the tumor growth was effectively inhibited by 
cGAMP treatment from 2569 mm3 to 967 mm3 and the mice survival rates were obviously increased from 40% up 
to 90% for 20 days. The mean tumor weight was significantly decreased from 2.5 g to 0.97 g in a dose-dependent 
manner by cGAMP treatment (Fig. 1C). These results showed that cGAMP possessed potent antitumor activity 
against murine Colon 26 adenocarcinoma, and the antitumor activity was dose-dependent. Deng, et al. reported 
activation of STING by a second messenger cGAMP administration enhanced antitumor immunity induced by 
radiation19. However, they did not find the antitumor activity of cGAMP alone without radiation. The unsuccess-
ful antitumor activity of cGAMP alone is likely due to low cGAMP dosage (0.5 mg/kg) and less administration 
times (only two times), compared with the amount of cGAMP (> 5 mg/kg) and administration for 20 days in our 
experiment.
cGAMP Induces Apoptosis of Tumor Cells. To understand how cGAMP suppressed tumor growth and 
increased survive rates of tumor-bearing mice, we examined apoptosis in tumor tissues. The tumor damage in the 
Figure 1. cGAMP Possesses Potent Anti-tumor Activity against Murine Colon 26 Adenocarcinoma. Colon 
26 tumor-bearing mice were treated with cGAMP from day 0 to day 20 with 5, 10 and 20 mg/kg, respectively. 
(A) Mean tumor volumes. (B) Survival rates of mice. (C) Tumor weights. Representative data are shown from 
three experiments conducted with 10 mice per group. Data are represented as mean ± SEM, *p < 0.05 and 
**p < 0.01 (Student’s t test in A and C, and log rank [Mantel-Cox] test in B).
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tumor-bearing mice, after cGAMP treatment (20 mg/kg) for 20 days, was determined by terminal deoxynucleoti-
dyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining and Hematoxylin-Eosin 
(HE) staining assays. Compared to the control group, severe cell apoptosis occurred in the tumor tissues upon 
cGAMP treatment as indicated by TUNEL staining (Fig. 2A). In the HE staining assay, the nuclei and their 
fragments of tumor cells are blue-violet and the cytoplasm is pink-red (Fig. 2B). The tumor tissues in control 
mice displayed typical tumor tissue pattern with blue-violet color when treated with cGAMP, and the tumor 
tissues changed clearly from blue-violet to pink-red. These results demonstrated that the therapeutic effect of 
cGAMP is due to the induction of tumor cells apoptosis. To investigate whether cGAMP can kill tumor cells 
directly, cytotoxicity of cGAMP on CT26 cells were performed by MTT assay. As shown in Figure S1, cGAMP 
(10–200 μ M) did not show obvious toxicity against CT26 cells and could not kill tumor cells directly in vitro. 
To investigate whether cGAMP induces apoptosis selectively in tumor cells, CD45 co-staining was preformed, 
and the results indicated that cGAMP selectively induced apoptosis of tumor cells while showing no impact on 
immune cells (Figure S2). Considering the role of cGAMP in STING pathway, we proposed that cGAMP might 
activate anti-tumor immunity through cGAS-cGAMP-STING-IRF3 innate immune pathway.
cGAMP Induces the Expression of Cytokines in Mice. To test whether cGAMP stimulates innate 
immune responses and triggers antitumor cytokines production, we examined the induction of cytokines, includ-
ing IFN-β , IFN-γ and other cytokines in the tumor-bearing mice. We observed that cGAMP up-regulated the 
expression levels of IFN-β and IFN-γ in the serum (Fig. 3A) and the mRNA levels of these cytokines in the tumor 
tissues (Fig. 3B). It has been shown that cGAMP serves as a second messenger to stimulate the production of 
Figure 2. cGAMP Induces Apoptosis of Tumors. (A) TUNEL assay of tumor tissues using the “In Suit Cell 
Death Detection Kit, Fluorescein” (Roche, Germany). (B) Hematoxylin-Eosin staining assay of tumor tissues in 
control group and cGAMP-treated tumor-bearing mice (20 mg/kg). The nuclei and their fragments are  
blue-violet and the cytoplasm is pink-red. Scale bar = 100 μ m. DAPI is 4,6-diamidino-2-phenylindole and 
TUNEL assay is terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay.
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IFN-β and other cytokines by direct binding to the adaptor protein STING in the innate immune pathway9,25. 
IFN-β production and dendritic cell activation may be triggered via the cGAS-cGAMP-STING-IRF3 innate 
immune pathway by cGAMP21,22. Diamond, et al. has shown that endogenously produced IFN-β is critical for the 
induction of an antitumor immune response resulting in the elimination of those tumors31. Targeting low doses 
of type-I IFNs to the tumor microenvironment promotes anti-tumor activity via host adaptive immunity that is 
T cell-dependent32. High doses of intratumoral injection IFN-β largely functioned via an anti-angiogenic effect33. 
IFN-γ can also induce tumor cell apoptosis and exerts an antitumor effect via a tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) pathway, which causes apoptosis in tumor cells by activating caspase-3 with 
the target cells20. Besides IFN-β and IFN-γ , we had also detected up-regulation of cytokines important in innate 
Figure 3. cGAMP Stimulates Cytokines Production. Colon 26 tumor-bearing mice were treated from day 0 
to day 20 with 20 mg/kg cGAMP. (A) Cytokines production of IFN-β , IFN-γ were measured by ELISA in serum 
at the 20th day and (B) Tumor tissues from tumor-bearing mice were detected by quantitative SYBR Green real-
time PCR. Representative data are shown from three experiments conducted with 10 mice per group. Data are 
represented as mean ± SEM, *p < 0.05 and **p < 0.01(Student’s t test).
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immune response like IL-2, IL-12, TNF-α , MCP-1 and down-regulation of IL-10 (Figure S3). Our results demon-
strated that cGAMP can trigger the production of cytokines including IFN-β and IFN-γ by stimulating antitumor 
immunity of immunogenic tumors.
cGAMP Triggers Dendritic Cells Activation. Dendritic cells (DCs), serve as antigen-presenting cells spe-
cialized to initiate and maintain immunity34. Resting DCs are immature and resident in most tissues and can be 
activated by environmental stimuli to mature into potent APCs. Murine DCs undergo phenotypic maturation 
upon exposure to type-I IFN in vivo or in vitro8. They play a pivotal role in the initiation, programming, and reg-
ulation of immunogenic tumors4,35. Previous study has shown that cGAMP can directly activate DCs in vitro36. 
To investigate whether cGAMP treatment is able to stimulate DCs activation in vivo, we evaluated the function 
of spleen DCs with CD40+, CD80+, CD86+ and MHC-II+ by flow cytometry analysis (Fig. 4A–C). As shown in 
Fig. 4D,E, all CD40+, CD80+, CD86+ and MHC-II+ of DCs were significantly up-regulated upon the cGAMP 
treatment in tumor-bearing mice. cGAMP stimulated and enhanced the antigen-presenting function of DCs, 
which establishes a potential to activate CD8+ T cells. cGAMP triggers DC activation by boosting the expres-
sion of IFN-β via the STING-dependent pathway9,19. IFN-β then induces the expression of the co-stimulatory 
molecules, such as CD40, CD80, CD86 and the MHC-II, and activate tumor-specific CD8+ T lymphocytes37,38. It 
has been reported that cGAMP is an adjuvant that stimulates T cell activation in a STING-dependent manner27. 
Consistent with previous study, we also had detected the increase in CD8+ T-cell (Figure S4) and up-regulation 
of related cytokines like IL-2 ,TNF-α and IFN-γ ( Figure S3 & Fig. 3).
cGAMP Stimulates the Expression of STING and IRF3 in Tumor Tissues. To further investigate 
whether cGAMP targets the STING in the cGAS-cGAMP-STING-IRF3 pathway to facilitate antitumor activity, 
we examined the expression of STING and IRF3 in tumor tissues treated with cGAMP by immunofluorescence 
assay. As shown in Fig. 5, the expression of both STING and IRF3 in the tumor tissues was obviously up-regulated 
by cGAMP treatment. The results demonstrated that cGAMP enhanced antitumor immunity in mice via the 
activation of STING and subsequent stimulation of the cGAS-cGAMP-STING-IRF3 pathway. It has recently been 
reported that IRF3 activation is part of the first line of defense against invading viruses by inducing the produc-
tion of IFN-β , and the induced amplification loop of type-I IFN leads to the development of an antiviral state10,22. 
We herein found that cGAMP stimulated the production of type-I IFN to exert antitumor effect via stimulating 
IRF3 activation.
STING Is Essential for the Antitumor Activity of cGAMP. Given that cGAMP exerts the antitumor 
effect via stimulating the innate immune pathway of cGAS-cGAMP-STING-IRF3 to enhance production of 
IFN-β , IFN-γ , as well as to activate DCs, STING is likely targeted directly by cGAMP to stimulate the innate 
immune response. To test this hypothesis, we conducted antitumor studies of cGAMP in STING−/− mice. We 
implanted Colon 26 tumor cells on flanks of wild-type (WT) and STING−/− mice (Tmem173−/−, STING is 
encoded by Tmem 173) and monitored tumor growth upon cGAMP treatment. Our results showed that tumor 
growth was significantly inhibited by the treatment with cGAMP in WT mice, while the absence of host STING 
significantly reduced the antitumor effect of cGAMP (Fig. 6). Compared with WT mice, interferon regulatory 
factors (IRF3) could not be activated in STING−/− mice (Figure S1B). cGAMP treatment could not induce 
the expression of IFN-β and IFN-γ in STING−/− mice (Figure S5B). As cGAMP triggered dendritic cells acti-
vation in wild-type mice, whether cGAMP could still activate DCs in STING−/− mice was investigated. As 
showed in Figure S6, cGAMP showed no effects on dendritic cells activation in STING−/− mice. These studies 
demonstrated that STING is essential for the antitumor activity of cGAMP, suggesting that STING-dependent 
cGAS-cGAMP-STING-IRF3 pathway plays a major role in cGAMP inducing tumor suppression. It is interesting 
to note that cGAMP still have some tumor suppressive activity in STING−/− mice (Fig. 6), indicating cGAMP 
may stimulate other STING independent pathways to suppress tumor growth when STING is absent.
Combination of cGAMP and 5-FU Improve the Antitumor Activity and Reduce the Toxicity of 
5-FU Chemotherapy. Combination of multiple drugs has showed better therapeutic efficacy in antitumor 
treatment. To test if cGAMP can boost the antitumor activity of 5-FU and reduce 5-FU-induced toxic side effects, 
we examined the antitumor activity of cGAMP in combination with 5-FU. We found that, with the combina-
tion of 5-FU and cGAMP treatment, tumor growth in mice (Fig. 7A,C,D) was inhibited much more effectively, 
and survival rate (Fig. 7B) was increased from 80% (treated with 5-FU alone) to 100% (treated with 5-FU plus 
cGAMP). Chemotherapy-induced mucosal barrier dysfunction can lead to nausea, vomiting, diarrhea, severe 
mucosal necrosis, blood in the stool and systemic adverse reactions, and even lead to disease progress39. The 
side-effects of 5-FU result in intestinal atrophy, as indicated by increased intestinal permeability and shorter 
villi, disorders in intestinal flora40,41. As shown in Fig. 7E, HE staining assay for small intestine structure showed 
that cGAMP does not induce obvious toxicity to intestinal tissue. The small intestine showed the same micro-
structure in cGAMP group as those in un-treated control group (Fig. 7E, leftmost panels); while 5-FU-treated 
group showed severe damage of the small intestinal epithelial tissue (Fig. 7E, the panels next to rightmost panels), 
resulting in mucosal atrophy. Interestingly, when the tumor-bearing mice were treated with 5-FU in combination 
with cGAMP, the damage of intestinal mucosal epithelial tissue was alleviated significantly (Fig. 7E, right most 
panels). Taken together, these studies have shown that cGAMP not only improve the antitumor activity of 5-FU 
significantly, but also reduce the toxicity of 5-FU, when using a combination therapy.
Discussion
Immunotherapy is revolutionizing the treatment of cancer patients. Great progresses have been 
recently made in understanding the structural basis and molecular mechanism of the newly discovered 
cGAS-cGAMP-STING-IRF3 pathway in innate immunity21–26. cGAS is an innate immune sensor of HIV and 
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Figure 4. cGAMP Triggers Dendritic Cells Activation. Colon 26 tumor-bearing mice were treated with 
cGAMP from day 0 to day 20 with 20 mg/kg once a day. Flow cytometry was applied to detect DCs from spleen 
with (A) isotype control, (B) key surface markers: CD40+, CD80+, CD86+ and MHC-II+ on 14th day and  
(C) 20th day, respectively, and calculated with Mean Fluorescence Intensity (MFI) (D,E). Representative data 
are shown from three experiments conducted with 10 mice per group. Data are represented as mean ± SEM, 
**p < 0.01 (Student’s t test in D and E).
www.nature.com/scientificreports/
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other retroviruses, and cGAS-cGAMP-STING-IRF3 signaling plays a pivotal role in antiviral defense and 
immune adjuvant effects22,27,30. cGAMP is a small second messenger molecule (675 Da) that binds to STING 
and triggers the innate immune responses for antiviral defense. Recently, more and more studies show 
STING mediated immune response is also critical in regulating antitumor immunity18,37,42. Direct activation 
of STING might provide a new strategy to improve cancer therapies. STING agonists such as DMXAA (5, 
6-dimethylxanthenone-4-acetic acid), c-di-GMP and cGAMP could provide a new therapeutic strategy.
In this study, we systematically studied the antitumor activity of cGAMP against murine Colon 26 adenocarci-
noma with mouse models. Our results showed that cGAMP has potent antitumor activity, which is dose depend-
ent. When used at the dosage of 20 mg/kg, the tumor inhibition rate at the 20th day was over 60%. The survival rate 
of WT tumor-bearing mice treated daily with cGAMP was still 70% for 40 days. In addition, in established tumor 
model, cGAMP still showed antitumor activity and the tumor inhibition rate was over 40% for 20 days cGAMP 
treatment (Figure S7). TUNEL assay and HE staining analysis of tumor tissues showed that cGAMP induced 
tumor cell nuclei lysis, apoptosis, and severe tumor tissue damage. To investigate whether cGAMP can kill tumor 
cells directly, cytotoxicity of cGAMP on CT26 cells was performed by MTT assay. The results indicated that 
Figure 5. cGAMP Boosts the Expression of STING and IRF3 in Tumor Tissues. Colon 26 tumor-bearing 
mice were treated with cGAMP from day 0 to day 20 with 20 mg/kg once a day. (A) STING (stimulator of 
interferon genes) and (B) IRF3 (IFN regulatory factor 3) were detected with immunofluorescence technique. 
Scale bar = 200 μ m.
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cGAMP did not show obvious toxicity against CT26 cells. Therefore, cGAMP can’t inhibit the growth of tumor 
cell directly. We suppose that cGAMP exerts antitumor effects through boosting the STING innate immune 
signaling pathway.
DCs are ideal antigen-presenting cells and can induce the cross-priming of CD8+ T cells8. Type-I IFN exert 
multiple effects on DCs, affecting the major cellular pathways associated to their antigen-presenting cell (APC) 
function, namely differentiation, maturation, and migration and up-regulation of MHC-I, CD40, CD80, CD86, 
and CD83 molecules resulting in a superior capacity to induce CD8+ T-cell responses18,43–45. Type-I IFNs, as stim-
ulators of DC-mediated cross-priming have critical impact on antitumor response, and are the prototype inflam-
matory cytokines released upon stimulation of the cGAS-cGAMP-STING-IRF3 immune pathway8,14. Therefore, 
DC-mediated cross-priming is crucial for antitumor immunity46.
In this study, analysis of host serum (by ELISA) and tumor tissue (by Real-time PCR) showed that cGAMP 
significantly up-regulated antitumor cytokines, such as IFN-β and IFN-γ . DCs from the spleen were activated 
by cGAMP, as assessed by flow cytometry with CD40+, CD80+, CD86+ and MHC-II+. These results demon-
strated that cGAMP stimulated DCs activation, and boosted the innate immune response of immunogenic tum-
ors. Tumor site analysis from immunofluorescence detection indicated that STING and IRF3 were significantly 
up-regulated upon cGAMP treatment. Whereas, the absence of host STING dramatically reduced the antitumor 
effect of cGAMP. These results provide evidence that using cGAMP stimulates and enhances the innate immune 
response through the cGAS-cGAMP-STING-IRF3 pathway, and increases antitumor cytokines production and 
DCs activation to inhibit tumor growth. As an endogenous second messenger in innate immune signaling by 
cytosolic DNA, cGAMP binds to STING and activates IRF3 in a STING-dependent manner and induce IFN-β 
production14. Endogenously produced IFN-β is critical for the induction of an antitumor immune response 
resulting in the elimination of tumors33.
Figure 6. STING Is Essential for the Antitumor Activity of cGAMP. WT and STING−/− (Tmem173−/−) mice 
were inoculated and treated with cGAMP (20 mg/kg) for twenty days. (A) Mean tumor volumes, (B) Tumor 
weights, (C) Tumor inhibition rate, (D) Survial of tumor mice were showed. Representative data are shown 
from three experiments conducted with 10 mice per group. Data are represented as mean ± SEM, *p < 0.05 and 
**p < 0.01 (Student’s t test).
www.nature.com/scientificreports/
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Figure 7. cGAMP with 5-FU Improve the Antitumor Activity and Reduce the Toxicity of 5-FU 
Chemotherapy. Colon 26 tumor-bearing mice were treated with cGAMP (5 mg/kg) and 5-FU (10 mg/kg) once 
a day. (A) Mean tumor volumes, (B) Survival rate of mice for twenty days. (C) Tumor weights. (D) Tumor 
inhibition rate. (E) Hematoxylin-Eosin staining for detection of small intestine tissues. Representative data 
are shown from three experiments conducted with 10 mice per group. Data are represented as mean ± SEM, 
*p < 0.05 and **p < 0.01 (Student’s t test in A, C and D, and log rank [Mantel-Cox] test in B).
www.nature.com/scientificreports/
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Many kinds of cancers appear to induce a spontaneous adaptive T cell response. Targeting low doses of type 
I IFNs to the tumor microenvironment also promotes anti-tumor activity via host adaptive immunity that is T 
cell-dependent8,16. The presence of T cell infiltrate has been linked to favorable clinical outcome in multiple types 
of cancers47,48. However, the innate immune pathways that bridge to an adaptive immune response under sterile 
conditions are poorly understood. This study revealed that cGAMP can induce IFN-β , IFN-γ production and 
DCs activation, which are required for a spontaneous T cell response in vivo. DCs secrete and respond to type-I 
IFN as autocrine DC activators38,45. Basal expression of type-I IFN by DCs leads to secretion of IFN-γ , which may 
in turn act to enhance DC activation38.
cGAMP can activate STING-IRF3 signaling pathway and stimulate IFN-γ expression9–13. In mPBMCs, syn-
ergistic production of innate IFN-γ was completely dependent on IRF3 and IRF7, which are required for the 
induction of type-I IFNs, and STING signaling pathway is response for type-I IFNs49. IFN-γ is a key cytokine 
in tumor immunology. IFN-γ is produced predominantly by T lymphocytes, NKT cells and natural killer (NK) 
cells50,51. IFN-γ is essential for rejection of transplanted tumor cells, destroys existing tumor stroma and decreases 
tumor development52.
Besides IFN-β and IFN-γ , cGAMP could regulate the expression of other cytokines (Figure S3). In 
tumor-bearing mice, IL-2, IL-6, IL-12, TNF-α , and MCP-1 were up-regulated while IL-10 was down-regulated 
after cGAMP treatment. IL-2 has been approved by the Food and Drug Administration (FDA) for the treatment 
of cancers. IL-6 is a pleiotropic cytokine secreted by many different cells, including the monocyte/macrophages, 
mast cells, T cells, and DCs. IL-6 influences antigen-specific immune responses and inflammatory reactions53. 
Just as Fisher DT et al. reviewed the two faces of IL-6 in the tumor microenvironment, while IL-6 signaling is 
generally considered as a key driver of malignancy, accumulating evidence establishes IL-6 is a key player in the 
mobilization of anti-tumor T cell responses54. IL-6 signaling can also resculpt the T cell immune response, shift-
ing it from a suppressive to a responsive state that can effectively act against tumors. IL-6 plays an indispensable 
role in boosting CD8+ T cell trafficking to tumor sites, where they have the opportunity to become activated 
and execute their cytotoxic effector functions, respectively54. IL-12 can act as a growth factor for activated T 
and NK cells, enhance the lytic activity of NK cells, and stimulate the production of IFN-γ by resting PBMC55. 
IL-12 regulates VEGF and MMP to exert potent anti-angiogenic effects which contribute to tumor regression 
in cancer model56. In addition, IL-12 with IFN-γ are important cytokines for tumor surveillance57. The role of 
MCP-1 in angiogenesis and tumor progression has been revealed, the expression level of MCP-1 is correlated 
with anti-tumor activity58,59. IL-10 suppresses anti-tumor immunity while T cell-derived IL-10 promotes cancer 
growth by suppressing both T cell and APC function60. Based on the roles of these cytokines in anti-tumor immu-
nity, the anti-tumor activity of cGAMP might be related to regulation of these cytokines, although how cGAMP 
tunes the protein expression levels of some cytokines is still unclear.
DMXAA, a vascular disrupting agent, can activate dendritic cells and possess strong anti-tumor activity in 
mouse models61,62. DMXAA binds mouse mSTING but not human hSTING, and has failed in clinical trials in 
non-small-cell lung cancer26,63. To evaluate safety of cGAMP, toxicity of cGAMP treatment was investigated. The 
toxicity of liver and kidney tissues induced by cGAMP was also examined by HE staining, and we found that 
cGAMP had no toxicity to liver and kidney (Figure S8). In addition, cGAMP treatment has no direct impact on 
T cells (Figure S9). As a natural ligand for hSTING, cGAMP might be more promising in antitumor drug design 
and discovery compared to DMXAA.
5-FU is a clinical antitumor drug with interference of DNA synthesis with obvious side-effects. According 
to NCCN guidelines in colon cancer (Version 1, 2014), adjuvant therapy with 5-FU alone or combination is 
not only recommended by the panel for patients with stage III disease but also for patients with high-risk stage 
II disease. Immunotherapeutic strategies maybe enhance the response to anticancer therapies. Here we found 
that cGAMP, as a stimulator/enhancer of innate immune antitumor agent, can not only improve the antitumor 
effects of 5-FU, but also attenuate the 5-FU-induced side-effects. The possible mechanism of cGAMP can reduce 
cytotoxicity of 5-FU maybe related to dendritic cells. Tadagavadi, R.K. et al. reported dendritic cells ameliorated 
cisplatin-induced nephrotoxic acute kidney injury and their protection from cisplatin nephrotoxicity was inde-
pendent of neutrophils64,65. cGAMP can enhance innate immune responses by inducing production of cytokines 
and stimulating dendritic cells activation, which may be able to reduces 5-FU-induced cytotoxicity. cGAMP 
alone is more suitable to patients with early stage colon cancer or prevent tumor recurrence or metastasis after 
chemotherapy or operation. The combination cGAMP with chemotherapy can supply to patients with high-risk 
stage II or stage III disease.
In summary, we have conducted the first systematic studies of the antitumor activity of cGAMP using mice 
models and its molecular mechanism against murine Colon 26 adenocarcinoma has been elucidated. Our results 
revealed that cGAMP has potent antitumor activity in mice through cGAS-cGAMP-STING-IRF3 pathway. 
Moreover, cGAMP can not only improve the antitumor activity of 5-FU, but also clearly reduce the toxicity of 
5-FU. These findings in the current study strongly suggest that cGAMP is likely to be potent for the treatment of 
colorectal cancer and demonstrated that the direct stimulation of the innate immune response by cGAMP has 
potential application in immunotherapy of cancer.
Methods
Preparation of cGAS and cGAMP. Mouse cGAS protein and cGAMP were prepared as described21,22. 
Briefly, mouse cGAS was cloned into a modified pET-28(a) vector with an N-terminal SUMO tag. The protein 
was expressed in E. coli BL21 (DE3) at 15 °C and purified by Ni-NTA and Superdex 200 gel filtration columns 
as described10,21. cGAMP was synthesized and separated as follows: cGAS was incubated with DNA in a reac-
tion buffer containing 20 mM HEPES (pH 7.5), 5 mM MgCl2, 2 mM ATP, and 2 mM GTP at 37 °C for 2 hours. 
The samples were centrifuged, passed through a 10 kD ultrafiltration filter (Millipore), analyzed and purified by 
ion exchange chromatography using a MonoQ column (GE Healthcare). cGAMP was further purified through 
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endotoxin removal kit (Thermo Fisher Scientific). Endotoxin level was tested using Pierce LAL Chromogenic 
Endotoxin Quantitation Kit (Thermo Fisher Scientific). Endotoxin-free cGAMP was lyophilized and stored at 
− 20 °C.
Mice and Cells. BALB/c mice (body weight: 20~25g) were obtained from SIPPR-BK Experimental Animal 
Co. (Shanghai, China). Tmem173−/− (STING-deficient) mice were purchased from the Jackson Laboratory in 
California USA. All the mice were maintained under specific pathogen-free conditions and used according to 
the animal experimental guidelines set by National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. This study has been approved by the Institutional Animal Care and Use Committee of Fudan University 
and the Scientific Investigation Board of Second Military Medical University, Shanghai. All animal experi-
ments were carried out in accordance with established International Guiding Principles for Animal Research. 
Colon 26 cells were cultivated in Dulbecco’s modified eagle media (Hyclone, USA), supplemented with 10% 
heat-inactivated fetal bovine serum (GIBCO, USA) containing penicillin/streptomycin at 37 °C under 5% CO2 
and 95% humidity incubator.
Tumor Growth and Treatments of Mice Models. Colon 26 adenocarcinioma cells (1 × 106) were 
injected subcutaneously into the right flank of mice. Mice were divided into 5 groups: (a) Control group with 
tumor cells injection; (b, c, d) tumor groups with tumor cells injection and treated with cGAMP at various dos-
ages of 5, 10 and 20 mg/kg, respectively; (e) Tmem173−/− (STING-deficient) mice group, with injection of tumor 
cells and treated with cGAMP (10 mg/kg). Four hours after injection of tumor cells, cGAMP was intravenously 
injected into the tumor-bearing mice daily for 20 days. Or cGAMP was intravenously injected daily after tumors 
were established. Tumors were measured and the weight of tumor-bearing mice was checked daily. On day 20th, 
all mice were weighed and sacrificed, and all the tumors were removed and weighed. According to the mean 
weight of tumors, the tumor inhibition rate was calculated as follows: the tumor inhibition rate (%) = [(mean 
tumor weight of control group − mean tumor weight of tumor group with cGAMP-treatments)/mean tumor 
weight of control group] × 100%.
ELISA. Mice blood serum samples were collected at ophthalmic vein and kept at room temperature for 2 h 
before centrifugation for 20 minutes at 1000g. The assay serum was freshly prepared. Concentration of IFN-β , 
IFN-γ , IL-2, IL-6, IL-10, IL-12, MCP-1 and TNF-α were measured with mouse ELISA kits (R&D Systems) 
according to the manufacture’s instruction, respectively.
Spleen Cell Isolation and Flow Cytometry. Spleen cells were isolated with the method described66. 
Briefly, murine spleen were disrupted and filtered through 40 μ m strainer to obtain single-cell suspensions. 
Splenocytes were resuspended in PBS buffer containing 0.5% BSA, and red blood cells were lysed with ACK 
lying buffer. Splenic CD11c+ DCs were labeled by CD11c mAb microbeads and isolated with MACS separation 
column (Miltenyi Biotec, Auburn, CA). Monoclonal antibodies including anti-mouse CD40, anti-mouse CD80, 
anti-mouse CD86 and anti-mouse MHC Class II were used for DCs detection. Purified DCs were incubated with 
antibody, respectively. For CD8+ T cells detection, splenic CD3+ CD8+ T cells were stained with both CD3 anti-
body and CD8α antibody. Monoclonal antibodies used for flow cytometry were all purchased from eBiosciences 
(San Diego, CA) and Flow cytometric analysis was performed on the BD FACS Cablibur flow cytometer (BD 
Bioscience, San Jose, CA).
RNA Extraction and Quantitative Real-Time PCR. Total RNA was purified from tumor tissues using 
TRIzol Reagent (Takara, Japan) and reversed-transcribed to cDNA with Prime Script TM RT Master Mix (Takara, 
Japan) according to manufacturer’s instructions. Real-time PCR was performed with Applied Biosystems 7500 
(Life Technologies Corporations, Carlsbad, CA, USA) with initial denaturation at 95 °C for 30 s, and followed 
by 40 cycles of denaturation (95 °C, 5 s), annealing (55 °C, 30 s), and extension (72 °C, 30 s). Relative expression 
changes were calculated with Δ Δ Ct method. GAPDH served as the internal control. The primer sequences are 
as follows:
GAPDH: Forward: 5′-CCAGCCCAGCAAGGATACTG-3′ 
Reverse: 5′-GGTATTCGAGAGAAGGGAGGGC-3′ 
IFN-β : Forward: 5′-TCCGAGCAGAGATCTTCAGGAA-3′ 
Reverse: 5′-TGCAACCACCACTCATTCTGAG-3′ 
IFN-γ : Forward: 5′-AGCAACAGCAAGGCGAAAA-3′ 
Reverse: 5′-CTGGACCTGTGGGTTGTTGA-3′ 
IRF3: Forward: 5′-AACCGTGGACTTGCACATCT-3′ 
Reverse: 5′-GCCATGCTGTGTTTTGTCCC-3′ 
Immunofluorescence. Tumor tissues were rapidly excised, rinsed with PBS buffer and fixed in 4% para-
formaldehyde. 5 μ m thick paraffin-embedded tumor sections were cut and deparaffinized in xylene and rehy-
drated in ethanol. The slides were blocked with 5% BSA, stained with primary antibody Tmem173 (Abcam, 
ab92605), IRF3 (Abcam, ab68481) or CD45 (Abcam, ab64100) with the dilution of 1:100, respectively, then 
stained with secondary antibody at 1:100, respectively. Then the slides were washed with PBS buffer and photos 
were taken with fluorescence microscope (Leica, Germany).
TUNEL Assay of Tumor Cells Apoptosis. Apoptotic tumor cells were determined by terminal deoxy-
nucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining (In Suit Cell 
Death Detection Kit, Fluorescein, Roche). For TUNEL assay, the slides were heated at 60 °C followed by washing 
in xylene and rehydration through a graded series of ethanol. Tissue sections with proteinase K were incubated 
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in working solution for 20 minutes, followed by TUNEL reaction mixture containing label and enzyme solution, 
with slide incubated in the dark. After rinsing the slide with PBS buffer, samples were analyzed under fluorescence 
microscope.
HE Staining. Tumor tissues, liver and kidney tissues were fixed in 4% paraformaldehyde for 24 h. 5 μ m thick 
section of tumor tissues were mounted on the slide and deparaffinized, and then stained with hematoxylin and 
Eosin (HE). The section was examined under light microscope (Leica, Germany)
MTT assay. CT26 cells were plated in 96-well culture plates at 5 × 104 cells/well, and incubated with cGAMP 
(10-200 μ M) for 48 h. Cell viability assay were performed using MTT method. MTT was added at a final concen-
tration of 5 mg/mL, after incubation at 37 °C for 4 h, the medium was removed and 150 μ L DMSO were added per 
well. The absorbance was measured at 490 nm.
CCK-8 assay. T Cells were purified with microbeads (MagniSort Mouse T cell Enrichment Kit, eBioscience) 
from spleen according to the manufacturer’s instructions. Cells were plated in 96-well culture plates and incu-
bated with cGAMP (10-200 μ M) for 48 h. 10 μ L CCK-8 solution was added to each well and cell viability was 
measured by a microplate reader at 450 nm.
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